Stereotactic radiotherapy with immunotherapy or targeted therapy for metastatic kidney cancer

This study looked at the safety and effectiveness of targeted therapies or immune checkpoint inhibitors (immunotherapy) in combination with stereotactic radiotherapy in patients with renal cell carcinoma (RCC). There were 53 patients in the study, of whom 32% were treated with immunotherapy and 68% targeted therapy. About a third of patients on targeted therapy paused […]

read more

ASCO 2021: Gut microbiome boosts nivolumab/ipilimumab activity

Recent evidence suggests that the bacteria in the gut (the gut microbiome) interacts with immune checkpoint inhibitors in metastatic renal cell carcinoma (RCC). In this study the bacterium Clostridium butyricum was investigated to see if it could modulate the gut microbiome in patients with metastatic RCC being treated with the nivolumab/ipilimumab combination and improve clinical […]

read more

Pegilodecakin for metastatic kidney cancer

Combinations of immunotherapy and vascular endothelial growth factor (VEGF) inhibitors have been proven to effective at improving survival for people with advanced or metastatic renal cell carcinoma (RCC). However, the role of a cytokine called interleukin-10 (IL-10) has been shown to enhance immunotherapy-induced anti-cancer activity. In this phase 1 trial, the safety, tolerability and preliminary […]

read more

ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer

The cabozantinib/nivolumab combination has been shown to be effective at improving survival in patients with metastatic clear cell renal cell carcinoma (RCC) in a phase 3 trial. This study, presented at the American Society for Clinical Oncology (ASCO) Annual Meeting held virtually over the weekend reports the results of a phase 2 trial of cabozantinib/nivolumab […]

read more

Risk of blood clots in cancer patients receiving immunotherapy

A recent study published in Blood has suggested that cancer patients who are being treated with immunotherapy, in particular immune checkpoint inhibitors are at high risk for blood clots (thromboembolism), especially blood clots in veins (venous thromboembolism). Although, the study does not show a causal link between immune checkpoint inhibitor therapy and blood clots. The […]

read more

Role of nephrectomy for metastatic kidney cancer in the immunotherapy era

Three phase III clinical trials (Keynote 426, Checkmate 9ER and Checkmate 214) assessing first-line treatment with immunotherapy in metastatic renal cell carcinoma (RCC) compared to sunitinib were analysed for patients who had prior nephrectomy compared to those who did not. Patients who had prior nephrectomy had a longer time before the immunotherapy stopped working and […]

read more

EIKCS 2021: Future treatments for metastatic kidney cancer

Despite the advances in first-line treatments for metastatic renal cell carcinoma (RCC) over the past few years, new treatments are on the horizon. In a presentation at the European International Kidney Cancer (EIKC) 2021 Virtual Annual Meeting, Dr Hans Hammers from University of Texas Southwestern Medical Center in the USA discussed future treatments for metastatic […]

read more

EIKCS 2021: Second-line and later treatments for metastatic kidney cancer

The increase in the number of first-line treatments for metastatic renal cell carcinoma (RCC) over the past 3 years has had meaningful effects on the choice of second-line treatments. Dr Camillo Porta from the University of Pavia in Italy discussed the selection of second-line and later treatments in a presentation at the European International Kidney […]

read more

EIKCS 2021: Combination therapies for metastatic kidney cancer: Which Approach?

The use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has increased significantly over the past 3 years. However, there are now a number of potential first-line treatments, and choosing the most suitable treatment for each individual patient can be difficult. In a presentation at the European International Kidney Cancer […]

read more

Effectiveness of second-line sunitinib after immunotherapy in metastatic kidney cancer

There is very little information on the effectiveness of sunitinib (a vascular endothelial growth factor (VEGF) inhibitor) as a second-line treatment after first-line treatment with immunotherapy for patients with metastatic renal cell carcinoma (RCC). A study published in Clinical Genitourinary Cancer last month looked at 102 patients in a real-world setting who were treated with […]

read more
Showing 1 to 10 of 292 results
  TOP